We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.


Clear all

Refine your search

Content type


Firm name



1,558 results found


Vinge | Sweden, European Union | 11 Jun 2019

Swedish Patent and Market Court of Appeal seeks clarification of the scope of the SPC Regulation in relation to new uses - refers question to the CJEU

In the beginning of May 2019 the Swedish Patent and Market Court of Appeal, requested a preliminary ruling from the Court of Justice of the European


Winston & Strawn LLP | USA | 23 Apr 2019

eDiscovery Advantage, Volume 5, Issue 1

The Winston & Strawn LLP eDiscovery and Information Governance Group (the "eDiscovery Group") is pleased to be able to offer our insights into the


Katz Marshall & Banks LLP | USA | 17 Apr 2019

Pharmaceutical Whistleblower Awarded $1.8M for Unlawful Retaliation

New Jersey’s Conscientious Employee Protection Act, N.J. Stat. 34:19-1 et seq. (“CEPA”), has resulted in another substantial whistleblower victory


Preu Bohlig & Partner | European Union, Germany | 16 Apr 2019

Reimbursement of Off-Label Use - Barriers and Limitations

One of the fundamental principles of EU pharmaceutical law is that a medicinal product may only be placed on the market on the basis of a marketing


Bird & Bird | Belgium, European Union | 5 Feb 2019

"Effective enforcement of EU competition rules in the pharmaceutical law remains a matter of high priority"

So notes the Commission's report on competition enforcement in the pharmaceutical sector (2009-2017) published at the end of January 2019. Who


McGuireWoods LLP | USA | 23 Jan 2019

Courts Issue Conflicting Work Product Doctrine Opinions: Part I

Ironically, federal and state courts applying their succinct work product rules exhibit more diversity than when construing the more complex and


Fenwick & West LLP | USA | 18 Dec 2018

Patent Owners Win as Federal Circuit Reins in Gilead and AbbVie Double Patenting Rulings

In a pair of patent owner victories, the U.S. Court of Appeals for the Federal Circuit issued decisions limiting the applicability of obviousness-type


Marshall Gerstein & Borun LLP | USA | 12 Dec 2018

Obviousness-Type Double Patenting Does Not Invalidate a Patent Term Extension

The Federal Circuit recently addressed the interplay between the statutory patent term extension (PTE) and the non-statutory doctrine of


Knobbe Martens | USA | 10 Dec 2018

Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical

A patent filed before the June 8, 1995 effective date of the Uruguay Round Agreements Act (URAA) has a 17 year term that begins on its issuance date


Pepper Hamilton LLP | USA | 10 Dec 2018

Obviousness-Type Double Patenting Just Became Less of a Problem for Innovators

The Federal Circuit recently issued a pair of decisions concerning the Gilead doctrine, which allowed later-issuing patents to be obviousness-type

Previous page 1 2 3 ...